Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 35, 2018 - Issue 1
Submit an article Journal homepage
204
Views
1
CrossRef citations to date
0
Altmetric
Solid Tumors and Neurooncology

Treatment of metastatic hepatocellular carcinoma in pediatric patients: Two case reports

Helen PearsonChildren and Young People´s Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United KingdomCorrespondence[email protected]
, BN (Hons) MSc, cANP,
A.S. KniselyInstitut für Pathologie, Medizinische Universitat Graz, Graz, Stiftingtalstrasse, Austria
, MD,
Maesha DeheragodaInstitute of Liver Studies, King's College Hospital, London, United Kingdom
, MD,
Stergios ZacharoulisPediatric Oncology, Harley Street Clinic, London, United Kingdom
, MD &
Fernando CarcellerChildren and Young People´s Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom;Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
, MD
Pages 90-94 | Received 31 Jul 2017, Accepted 19 Mar 2018, Published online: 13 Apr 2018

References

  • Schmid I, Häberle B, Albert MH, et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer. 2012;58(4):539–544. doi:10.1002/pbc.23295. PMID: 21922643.
  • Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the international society of pediatric oncology group. J Clin Oncol. 2002;20(12):2798–2804. doi:10.1200/JCO.2002.06.102. PMID: 12065556.
  • Murawski M, Weeda VB, Maibach R, et al. Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol. 2016;34(10):1050–1056. doi:10.1200/JCO.2014.60.2250. PMID: 26811523.
  • Allan BJ, Wang B, Davis JS, et al. A review of 218 pediatric cases of hepatocellular carcinoma. J Pediatr Surg. 2014;49(1):166–71; discussion 171. doi:10.1016/j.jpedsurg.2013.09.050. PMID: 24439603.
  • Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs. 2008;68(2):251–258. doi:10.2165/00003495-200868020-00007. PMID: 18197728.
  • Navid F, Christensen R, Inaba H, et al. Alternative formulations of sorafenib for use in children. Pediatr Blood Cancer. 2013;60(10):1642–1646. doi:10.1002/pbc.24619. PMID: 23788485.
  • Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol. 2007;59:183–195. doi:10.1007/s00280-006-0257-y. PMID: 16724239.
  • Nagel C, Armeanu-Ebinger S, Dewerth A, et al. Anti-tumor activity of sorafenib in model of pediatric hepatocellular carcinoma. Exp Cell Res. 2015;331:97–104. doi:10.1016/j.yexcr.2014.10.018. PMID: 25447203.
  • Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumours and leukemias: a children's oncology group phase I consortium report. Clin Cancer Res. 2012;18(21):6011–6022. doi:10.1158/1078-0432.CCR-11-3284. PMID: 22962440.
  • Vincent P, Zhang X, Chen C, et al. Chemotherapy with the Raf kinase inhibitor BAY43-9006 in combination with irinotecane vinorelbine or gemcitabine is well tolerated and efficacious in preclinical xenograft models [abstract]. Proc Am Soc Clin Oncol. 2002;21:a1900.
  • Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857. PMID: 18650514.
  • Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–125. doi:10.1016/S0140-6736(11)61347-0. PMID: 22353262.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.